Browsing All of EconStor by Author Dintsios, Charalabos-Markos
Showing results 1 to 5 of 5
Year of Publication | Title | Author(s) |
2014 | Patient relevant endpoints in oncology: Current issues in the context of early benefit assessment in Germany | Dabisch, Inna; Dethling, Jürgen; Dintsios, Charalabos-Markos; Drechsler, Melanie; Kalanovic, Daniel; Kaskel, Peter; Langer, Frank; Ruof, Jörg; Ruppert, Thorsten; Wirth, Daniel |
2016 | Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany: Are additional data requirements by the Federal Joint Committee justified? | Ruof, Jörg; Staab, Thomas; Dintsios, Charalabos-Markos; Schröter, Jakob; Schwartz, Friedrich Wilhelm |
2018 | Market withdrawals' of medicines in Germany after AMNOG: A comparison of HTA ratings and clinical guideline recommendations | Staab, Thomas R.; Walter, Miriam; Mariotti Nesurini, Sonja; Dintsios, Charalabos-Markos; von der Schulenburg, Johann-Matthias; Amelung, Volker E.; Ruoff, Jörg |
2020 | Predictors of negotiated prices for new drugs in Germany | Gandjour, Afschin; Schüßler, Sofia; Hammerschmidt, Thomas; Dintsios, Charalabos-Markos |
2021 | How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG? | Dintsios, Charalabos-Markos; Chernyak, Nadja |